Annals of Surgical Oncology Cite Track
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9521-6
Annals of Surgical Oncology 14:3154-3158 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ishigami, S.
Right arrow Articles by Aikou, T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ishigami, S.
Right arrow Articles by Aikou, T.

Original Article

Clinical Implication of CXCL12 Expression in Gastric Cancer

Sumiya Ishigami, MD, PhD, Shoji Natsugoe, MD, PhD, Hiroshi Okumura, MD, PhD, Masataka Matsumoto, MD, PhD, Akihiro Nakajo, MD, PhD, Yoshikazu Uenosono, MD, PhD, Takaaki Arigami, MD, PhD, Yasuto Uchikado, MD, PhD, Tetsuro Setoyama, MD, PhD, Hideo Arima, MD, PhD, Shuichi Hokita, MD, PhD and Takashi Aikou, MD, PhD

Digestive Surgery Surgical Oncology, Kagoshima University School of Medicine, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan

Correspondence: Address correspondence and reprint requests to: Sumiya Ishigami, MD, PhD; E-mail:. ishiga{at}m.kufm.kagoshima-u.ac.jp

Purpose: Recent research has revealed that tumor cells expressing chemokine receptors have a crucial impact on patient survival. However, there is no information regarding chemokine expression in gastro-intestinal cancer. This study immunohistochemically investigated CXCL12 expression in gastric cancer and evaluated its association with clinical factors, including patient prognosis.

Method: A total of 185 gastric cancer patients receiving curative gastrectomy were assessed. CXCL12 expression was evaluated by immunohistochemical analysis. Tumors with CXCL12-positive cancer cells were regarded as CXCL12 positive, and according to the degree of CXCL12 expression, patients were divided into three groups (weak, 31 cases; moderate, 27 cases; strong, 20 cases). Correlations between CXCL12 expression and clinical factors in gastric cancer were then determined.

Results: CXCL12 was found in the cellular membrane of cancer cells. Seventy-four of 185 patients were classified into the CXCL12-positive group. Patients were divided into three groups according to the positivity of CXCL12 expression. Significant associations between CXCL12 and lymph node metastases (p < 0.05), depth of invasion (p < 0.01), lymphatic invasion (p < 0.01), tumor diameter (p < 0.05), and clinical stage (p < 0.01) were seen. Univariate analysis revealed that the CXCL12-positive group had significantly poorer surgical outcome than the CXCL12-negative group (p < 0.01). Multivariate analysis revealed CXCL12 to be an independent prognostic factor in gastric cancer (p = 0.02).

Conclusion: Cancerous CXCL12 positivity was determined to be an independent prognostic factor in gastric cancer, with CXCL12-positive gastric cancer showing more-aggressive behavior. Autocrine CXCL12 secretion from tumor cells may activate CXCR-4 on the tumor cells, which may be related to of the viability of distant metastases.

Key Words: Gastric cancer • CXCL12 • Prognostic factor






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.